Opus announces recommendation for IDMC for Phase 1/2 trial of OPGx-BEST1

Opus Genetics (IRD) announced that the Independent Data Monitoring Committee, IDMC, issued a positive recommendation to continue as planned in the Company’s Phase 1/2 BEST1 clinical trial, BIRD-1, which is a multi-center, adaptive, open-label, dose-exploring study evaluating OPGx-BEST1 in participants with Best disease. “We are thrilled with this outcome from the first participant, whose encouraging safety results at one month enable us to proceed with dosing the next four participants in our BEST1 Phase 1/2 trial,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “The IDMC’s safety review and recommendation to continue the trial reinforces our confidence as we advance this program. BEST1-associated retinal diseases constitute a substantial unmet medical need, and this progress with OPGx-BEST1 represents an important step toward potentially preserving and restoring visual function for patients with Best disease.”